How we identified the potential opportunity, volume and markets for a new travel vaccine
Our client needed exploratory research to determine the global opportunity for a new travel vaccine in the private market. It was crucial to determine: which markets had the highest potential to purchase the vaccine in the private market, based on volume of travelers to appropriate regions and the nature of travel, who the key stakeholders were in each market, in terms of involvement with travel vaccine recommendation, prescribing and purchasing and finally receptivity to the vaccine in question.
Conference Live infographic
Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients real-time feedback and insight into delegates’ reactions as they happen. Our approach is very successful at engaging respondents, offers rich insights and immediate outputs.
The Cost of Counterfeits
The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.
If you discover the Rolex watch you bought on holiday is not a bargain but actually a fake you’d be pretty peeved, but other than a hit to the wallet and maybe to your pride you would be no worse off. If you took a counterfeit drug on the other hand, the consequences could be far more serious.
In 2011 the World Economic Forum estimated that the sales of counterfeit medicine had reached $200 billion; an increase of 90% since 2005, contributing to approximately 10% of all pharmaceutical sales globally. In developed markets, counterfeit drugs only account for around 1% of sales, but in ‘pharmerging countries’ such Africa, Asia and South America they are estimated to be accountable for up to 33% of pharmaceutical sales. With 1% of 4 billion prescriptions in the US amounting to 40 million prescriptions in the US each year, even in the west, counterfeiting is no small problem. The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.
Self-pay and Emerging Markets
A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public reimbursement of medication is often partial to non-existent, particularly in the outpatient setting. In this video Emerging Markets Director Marc Yates discusses the opportunities and challenges for pharma in self-pay markets and outlines what these mean for healthcare market research.
Therapy Watch HCV expands into 4 additional EU markets
The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space of time; from treating the disease to effectively curing it. With further products scheduled to come into the market in the next 6 months, it is becoming an increasingly competitive market.
As of September 2016 Therapy Watch HCV will be adding the 4 additional EU markets of Austria, Portugal, Switzerland & Sweden to our existing EU HCV tracker, which already covers the 5 markets of France, Germany, Italy, Spain and the UK. In these EU5 markets we currently interview 50 specialists, collecting 7 dynamic and 7 total records from each with 700 PRFs in each market per quarter. In the 4 smaller additional European markets we will be interviewing 15 physicians per quarter, with each completing 5 dynamic and 5 total records.